BioCentury
ARTICLE | Company News

Inhibitex, 3M deal

March 30, 2009 7:00 AM UTC

3M returned to Inhibitex rights to develop diagnostics using Inhibitex's IP covering ClfA and additional MSCRAMM protein targets. Inhibitex said it has no plans to develop or license the technology a...